简体中文

Press releases

01 Jul 2022

JIXING Announces the First Patient Enrollment in Phase 3 Study of Etripamil in China

Read article
29 Jun 2022

JIXING Announces Receipt of Clinical Trial Application Approval for China Cohort of Phase 3 Clinical Trial of Aficamten

Read article
09 May 2022

Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Read article
20 Apr 2022

JIXING Announces Leadership Transition

Read article
14 Apr 2022

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

Read article
31 Mar 2022

JIXING Announces the Appointment of Kun Wu as the Chief Commercial Officer

Read article
Load more

Developing innovative cardiometabolic therapies globally

Copyright © 2025 CORXEL. All Rights Reserved.
Designed & built by SampsonMay

沪ICP备20017872号-3

沪公网安备31010602008424号